Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index decreased by 0.59% as of July 30, 2025, with mixed performance among constituent stocks [1] - Dongxin Co., Ltd. led the gains with an increase of 18.63%, while Shengyi Electronics fell by 5.66% [1] - The Huaxia Sci-Tech 100 ETF (588800) dropped by 0.56%, with a recent price of 1.07 yuan, but saw a weekly increase of 5.06% as of July 29, 2025 [1] Group 2 - The State Council Information Office recently held a press conference discussing the high-quality completion of the 14th Five-Year Plan, focusing on deepening medical insurance reform [1] - The National Medical Insurance Administration emphasized the principle of "anti-involution" in the 11th batch of centralized procurement, aiming to optimize procurement rules [1] - The impact of centralized procurement on drug prices in the pharmaceutical industry has been significant, but expectations for price stabilization may lead to gradual improvement in profitability [1] Group 3 - Zhongyin Securities noted a shift in policy attitudes towards the pharmaceutical sector, with optimized procurement rules and a recovery phase for R&D pipelines [2] - The trend of overseas business development in the pharmaceutical industry is accelerating, showcasing the global competitiveness of China's innovative drugs [2] - The Huaxia Sci-Tech 100 ETF (588800) closely tracks the Sci-Tech 100 Index, focusing on high-growth sectors such as semiconductors, pharmaceuticals, and new energy [2]
“反内卷集采”催化医药版块估值重塑在即,科创100ETF华夏(588800)近一周累计涨幅达5%!
Mei Ri Jing Ji Xin Wen·2025-07-30 07:12